Payload Information
General Information of This Payload
| Payload ID | PAY0TKHIK |
|||||
|---|---|---|---|---|---|---|
| Name | P1 payload |
|||||
| Synonyms |
P1 payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C47H44ClFN6O6S |
|||||
| Isosmiles | COC1=C(C2=NC(COC3=C(C[C@](C(O)=O)(OC4=C(C5=NC=N4)C(C6=C(C)C(Cl)=C(OCCN7CCN(CC7)C)C=C6)=C(S5)C8=CC=C(F)C=C8)[H])C=CC=C3)=CC=N2)C=CC=C1 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C47H44ClFN6O6S/c1-29-34(16-17-38(42(29)48)59-25-24-55-22-20-54(2)21-23-55)40-41-45(51-28-52-46(41)62-43(40)30-12-14-32(49)15-13-30)61-39(47(56)57)26-31-8-4-6-10-36(31)60-27-33-18-19-50-44(53-33)35-9-5-7-11-37(35)58-3/h4-19,28,39H,20-27H2,1-3H3,(H,56,57)/t39-/m1/s1
|
|||||
| InChIKey |
PKYIMGFMRFVOMB-LDLOPFEMSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
875.423 |
Polar area |
132.26 |
||
Complexity |
2670.506222 |
xlogp Value |
8.87172 |
|||
Heavy Count |
62 |
Rot Bonds |
16 |
|||
Hbond acc |
12 |
Hbond Donor |
1 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Tumor Growth Inhibition (TGI) | 108.4 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 111.6 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 115.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 162.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 189.5 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 189.5 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 89.1 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.7 | nM |
NCI-H929 cells
|
Plasma cell myeloma, Multiple myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >3000 | nM | Undisclosed | Undisclosed | Undisclosed |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
CD74 Milatuzumab DANAPAE152C S375C-P2-L13-P1 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.217 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P2-L13-P1 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L27-P1 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.269 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L27-P1 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L11-P1 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.42 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L11-P1 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L35-P1 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.853 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L35-P1 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||